2-deoxy-D-glucose + docetaxel

**2-deoxy-D-glucose + docetaxel** is an investigational combination of two agents: - **2-deoxy-D-glucose (2DG)** is a synthetic glucose analog that inhibits glycolysis, selectively targeting cancer cells' altered metabolism by depleting cellular energy, increasing oxidative stress, and inducing apoptosis and autophagy. It also interferes with N-linked glycosylation, leading to protein misfolding and cell death[2][5][10]. - **Docetaxel** is a cytotoxic antineoplastic drug of the taxane class that stabilizes microtubules and prevents cell division. This combination is designed to exploit both agents’ complementary mechanisms: 2DG impairs tumor cell glucose metabolism (especially effective against hypoxic, glycolytic tumor cells), and docetaxel induces cell cycle arrest and apoptosis. Trials suggest no significant pharmacokinetic interaction between the agents, and the combination may improve therapeutic efficacy compared to either alone in advanced solid malignancies. The recommended phase I dose is 63 mg/kg/day of 2DG combined with weekly docetaxel administration, showing mainly manageable adverse effects. Development is focused on advanced solid tumors with evidence of disease stabilization in some patients[1][4][7][9].

Brand names

none known

Other names

2DG + docetaxel